Clinical Trial Search

Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms

Primary: Change From Baseline to Week 24 in Muscle Strength — 0.4 score on a scale

Primary: Number of Participants With AEs and SAEs — 14; 5; 14; 6 Participants

Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…

Primary: The Difference Between Touch Detection Thresholds From the Sensorimotor Evaluation at Baseline and After 10 Weeks of Induction Therapy. — 0.00; 0.06; 0.08; 0.13 mN…

Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615

Primary: Percentage of Complete Remission — 4; 3 Participants

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants

Primary: Body Mass Index (BMI) — 30.7 kg/m^2

Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838

Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005

Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…

Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256

Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters

Primary: To Determine the Effect of Acupuncture on Quality of Life in Patients With MG — 10.8; 9.4; 3.6; 8.3 score on a scale

Primary: Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. — 17; 6…

Primary: Walking Endurance — 42; 25 meters

Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001

Primary: Geometric Mean Titer Ratio for Each Vaccine Strain — 3.76; 3.53; 2; 1.46 geometric mean titer ratio — p=<.05

Primary: Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance — 12.40; 20.11 meters

Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…

Primary: Number of Participants With Survival — 66; 64 Participants

Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm

Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47

Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672

Primary: Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks — 32.16; 33.88; -1.96; -3.27 volts

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Remission Status — 39; 13 Participants — p=0.001

Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001